Monday, November 17, 2014 9:12:52 AM
8:40a ET November 17, 2014 (Benzinga)
Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX) with a Buy rating.
The target price for Mast Therapeutics is set to $3.
Mast Therapeutics' shares jumped 11.11% to $0.50 in pre-market trading.
Latest Ratings for MSTX DateFirmActionFromTo
Nov 2014Canaccord GenuityInitiates Coverage onBuy Oct 2013Canaccord GenuityInitiates Coverage onBuy
View More Analyst Ratings for MSTX
View the Latest Analyst Ratings
Recent MSTX News
- NYSE and Nasdaq Pull ETF Options Requests, 75% of Bitcoins Remain Inactive, MakerDAO Halts WBTC Loans • IH Market News • 08/16/2024 07:25:47 PM
- Deutsche Bank Faces Shareholder Backlash, Bank of America Sponsors 2026 World Cup, Quanterix CEO Buys More Shares • IH Market News • 08/16/2024 10:03:21 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM